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Abstract We show the presence of the tyrosine kinase JAK2 in human platelets and demonstrate that it undergoes phosphorylation on tyrosine 
residues on challenge with the G protein receptor stimulus, thrombin, or the tyrosine phosphatase inhibitor, peroxovanadate. Thrombin-induced 
phosphorylation of JAK2 is inhibited by two structurally distinct inhibitors of tyrosine kinases, staurosporine and the tyrphostin ST271. The protein 
kinase C (PKC) inhibitor, Ro 31-8220, and intracellular Ca*’ chelator, BAPTA-AM, also inhibit thrombin-induced phosphorylation of JAK2, while 
the phorbol ester, phorbol dibutyrate (PDBu), and Ca” ionophore, A23 187, induce tyrosine phosphorylation of JAKZ. These results suggest hat 
tyrosine phosphorylation of JAK2 stimulated by thrombin may be mediated downstream of phosphoinositide metabolism. 
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1. Introduction 
There is a marked increase in protein tyrosine phosphoryla- 
tion in association with platelet activation by a wide variety of 
agonists which occurs in three distinct phases, namely rapid, 
intermediate and late-stage events [l-3]. The latter stages of 
tyrosine phosphorylation are associated with activation of the 
fibrinogen receptor and onset of platelet aggregation [ 1,2]. The 
significance of the early stage of tyrosine phosphorylation in 
platelet activation is uncertain. 
The majority of agonists induce platelet stimulation through 
activation of phospholipase C which hydrolyses phosphoinosi- 
tides generating diacylglycerol (DG) and inositol 1,4,5-tris- 
phosphate (IP,). The former activates PKC and the latter re- 
leases calcium from intracellular stores. Stimuli which activate 
seven transmembrane receptors such as thrombin and throm- 
boxanes induce activation of phospholipase Cg isoforms 
through a G protein-dependent pathway [4], while other stim- 
uli, such as collagen and immune complexes, are thought to 
induce activation of phospholipase Cy isoforms through a tyro- 
sine kinase-dependent pathway [5,6]. 
Recently, a new family of tyrosine kinases, called the JAK 
family (Janus kinase or just another kinase), has heen identified 
and implicated in signal transduction induced by cytokines and 
growth factors (for review see [7-91). The family currently con- 
sists of four members, JAKl, JAK2, JAK3 and TYK2, which 
act in combination or in isolation depending on the stimulus 
[lO_141. For example, JAK2 plays an important role in mito- 
genesis induced by the haematopoietic factor, erythropoetin, in 
myeloid cells by virtue of its association to the membrane- 
proximal region of the erythropoietin receptor and subsequent 
activation [ 141. The JAK family of kinases induce gene regnla- 
tion through a miscellaneous family of proteins known as 
STATS (signal transducers and activators of transcription) 
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Abbreviations: BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-N,N, 
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TBS-T, Tris buffered saline-Tween; SDS-PAGE, sodium dodecyl 
sulphate-polyacrylamide g l electrophoresis; BSA, bovine serum albu- 
min; PMSF, phenylmethanesulphonyl difluoride. 
[9,15]. The existence of this new family of tyrosine kinases in 
haemotopoietic cells prompted us to investigate their presence 
in platelets. 
2. Materials and methods 
2.1. Reagents and materials 
Staurosporine, indomethacin, protein A-sepharose CL4B, Tween 
20, thrombin, A23187. uhenvlmethanesulphonyl difluoride (PMSF), 
PDBu and bovine se& albimin (BSA) fraction V were purchased 
from Siema (Poole. Dorset. UK). Antisera against JAKI and JAK2 _ \ , 
and the anti-phosphotyrosine monoclonal antibody, 4Gl0, were from 
Upstate Biotechnology Inc., (TCS Biologicals Ltd., Buckinghamshire, 
UK). Affinity-purified anti-JAK2 and anti-TYK2 were obtained from 
Santa Cruz Biotechnology (NBS Biologicals, Hatfield, UK). Horse- 
radish peroxidase-conjugated sheep anti-mouse IgG and donkey anti- 
rabbit IgG antibodies (NA931 and NA934), ECL reagents and Hyper- 
film were from Amersham International (Cardiff, UK). BAPTA-AM 
was from Calbiochem (Calbiochem-Novabiochem, Nottingham, UK). 
Triton-Xl00 was purchased from BDH-Merck (Poole, Dorset, UK). 
ST271 was kindly donated by the Wellcome Foundation. Ro 31-8220 
was a gift from Roche Products (Welwyn Garden City, Herts., UK). 
Polyvinylidene difluoride (PVDF) membranes were from Bio-Rad 
(Bio-Rad Laboratories Ltd., Hertfordshire, UK). All other reagents 
were of analytical grade. 
2.2. Platelet isolation and stimulation 
Human platelets were isolated from aspirin-free donors on the day 
of the experiment as described previously [16] and, following two wash- 
ings, resuspended at a concentration of 4-8 x 10’ cells/ml in a modified 
Tyrode buffer (134 mM NaCl, 2.9 mM KCl, 0.34 mM Na,HPO,, 12 
mM NaHCO,, 20 mM HEPES, 1 mM MgCl,, 5 mM glucose, pH 7.3) 
containing indomethacin (10 PM) and EGTA (1 mM). All experiments 
were performed at 37°C. Platelet suspensions (0.4 ml) were prewarmed 
for 5 min before addition of compounds (14 ~1) and incubated for the 
times indicated before addition of the stimulus. Peroxovanadate was 
generated by adding orthovanadate (400 PM) 60 s before H,O, 
(2 mM). 
2.3. Immunoblotting 
Samples of platelets (4 x lO’/ml) were heated for 5 min at 100°C in 
Laemmli buffer. Proteins were separated by 10% SDS-PAGE and 
transferred to PVDF blotting membranes by semi-dry transfer (120 
min, 15 V). Non-specific binding was blocked with Tris-buffered saline- 
Tween (TBS-T: 20 mM Tris-HCl, pH 7.6, 137 mM NaCl, 0.1% Tween 
20) containing 10% BSA (w/v). Membranes were incubated with the 
primary antibody dissolved in the same buffer (1 ,@ml anti-phosphoty- 
rosine 4Gl0, 1: 500 dilution anti-JAKl serum, 1: 1000 dilution anti- 
JAK2 serum and 0.1 &ml anti-TYK2 antibody) for 60 min at room 
temperature. Membranes were washed five times in TBS-T before de- 
tection of bound antibody with horseradish peroxidase-conjugated 
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sheep anti-mouse IgG (NA 931) or donkey anti-rabbit IgG (NA 934), 
depending on the nature of the first antibody. After washing, the blots 
were treated with ECL reagents and exposed to Hyperfilm. Membranes 
were stripped of bound antibody by washing in TBS-T containing 2% 
SDS for 40 min at 80°C. After verifying the stripping through the use 
of the secondary antibody, blots were re-probed with a different pri- 
mary antibody as appropriate. 
2.4. Immunoprecipitation 
Immunoprecipitation of proteins carried out under non-denaturing 
conditions was performed as follows: platelets (8 x 10*/m]) were lysed 
in 1% Triton X-100.150 mM NaCl. 10 mM Tris. 0.5 mM PMSF. 5 mM 
EDTA, 1 mM Na,$O, for 30 min at 4’C. Samples were centiifuged 
5 min at 13,000 x R and supernatant was pre-cleared with 40~1 of 
protein A-Sepharoie CL 4B.After adding the antibody (1: 300 dilution 
for anti-JAK2 serum. 1 &ml for anti-JAK2 and anti-TYK2 antibod- 
ies) and 40 ~1 of pro&&i-Sepharose CL 4B, samples were left to mix 
gently overnight and then centrifuged at 13,000 x g and the pellet 
washed twice with extraction buffer and twice with TBS-T. Im- 
munoprecipitated protein was solubilized in Laemmli buffer, boiled for 
10 min at lOO”C, separated by 10% SDS-PAGE and analysed by im- 
munoblotting as detailed before. 
Immunoprecipitation in denaturing conditions was carried out with 
the use of 2% SDS in the extraction buffer. The samples were then 
diluted 1: 20 in TBS-T containing 2 mg/ml BSA, 1 mM PMSF and 
1 mM EDTA; subsequent steps were the same as for immunoprecipita- 
tion under the non-denaturing conditions described above, except that 
a 1: 20,000 dilution for anti-JAK2 serum was used. 
3. Results 
3.1. Presence of JAK2 and tyrosine phosphorylation 
Western blotting revealed the presence of JAK2 (- 125 kDa) 
and TYK2 (- 135 kDa) in human platelets (Fig. 1A). Both pro- 
teins were weakly phosphorylated on tyrosine residues under 
basal conditions. However, only JAK2 underwent an increase 
in phosphorylation on tyrosine residues in platelets challenged 
with thrombin or the tyrosine phosphatase inhibitor, peroxova- 
nadate, in the absence of aggregation (Fig. 1B). Stripping of 
blots and reprobing with anti-JAK2 confirmed that the increase 
in tyrosine phosphorylation was due to incorporation of phos- 
phate rather than recovery of more protein (Fig. 1B). Tyrosine 
phosphorylation of JAK2 induced by either stimulus was slow 
in onset relative to several platelet responses, including secre- 
tion and shape change, with significant increases being detected 
only 30-60 s after stimulation; phosphorylation was main- 
tained for at least 10 min (Fig. 2). Thrombin-induced a similar 
increase in tyrosine phosphorylation of JAK2 under conditions 
which enabled platelet aggregation to take place, i.e. absence 
of EGTA (not shown). The increase in tyrosine phosphoryla- 
tion of JAK2 induced by thrombin was inhibited completely by 
staurosporine (10 ,uM), a non-specific inhibitor of both serinel 
threonine and tyrosine kinases [5], and by the tyrphostin ST27 1 
(300 PM) [17], a more selective inhibitor of tyrosine kinases 
(Fig. 3A). 
3.2, Relationship of phosphorylation of JAK? to 
phosphoinositide metabolism 
Since signal transduction by thrombin involves synergistic 
effects mediated through the mobilization of Ca*’ and activa- 
tion of PKC, we examined the role of these second messenger 
pathways in the regulation of JAK2 phosphorylation. The PKC 
inhibitor Ro 31-8220 (10 PM) and intracellular Ca*’ chelator 
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Fig. 1. (A) Presence of JAK2 and TYK2 in human platelets. Whole cell lysates were immunoblotted as described in section 2. The results with JAK2 
were obtained with the antiserum from Upstate Biotechnology Inc. (UBI) which was raised against residues 758-776 of murine JAK2; similar results 
were obtained with a second JAK2 antibody from Santa Cruz Biotechnology raised against a peptide corresponding to amino acids 1110-l 129 of 
murine JAK2 (not shown) (B) Upper panel: JAK2 undergoes tyrosine phosphorylation on activation of platelets with thrombin (1 unit/ml) (lane 2) 
and peroxovanadate (400 PM sodium vanadate/4 mM H,O,) (lane 3). Lane 1 shows weak basal tyrosine phosphorylation. Platelets (8 x 108/ml) were 
stimulated for 3 min at 37°C under stirring. Samples were lysed in non-denaturing conditions and JAK2 was immunoprecipitated with anti-JAK2 
antibody from Santa Cruz Biotechnology, separated and immunoblotted with antiphosphotyrosine as detailed above. The 80 kDa band observed 
in thrombin-stimulated platelets was observed in some but not all studies, and could be revealed through the use of the secondary antibody alone. 
Lower panel: Western blot of anti-JAK2 for the same region of the membrane, following removal of the antiphosphotyrosine antibody (see section 
2). In all cases, similar results were obtained in at least three other experiments. 
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Fig. 2. Time-course for tyrosine phosphotylation of JAK2 induced by thrombin (1 unit/ml) (A) or peroxovanadate (4OOpM sodium vanadatelrl mM 
H,O*) (B). Platelets (8 x lO*/ml) were challenged with thrombin or peroxovanadate at 37°C for the time indicated. Cells were lysed and protein 
immunoprecipitated in denaturing conditions with anti-JAK2 serum from UBI. The immunoprecipitates were submitted to SDS-PAGE and protein 
was transfered to membrane and probed with antiphosphotyrosine antibody (see section 2). Two other experiments gave similar results. 
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BAPTA-AM (40 ,uM) were used to investigate whether throm- 
bin induces phosphotylation of JAK2 through an increase in 
Ca’+ and/or activation of PKC [6]. Neither Ro 31-8220 or 
BAPTA-AM altered the degree of tyrosine phosphorylation of 
JAK2 under basal conditions (results not shown). However, 
both agents markedly inhibited tyrosine phosphorylation of 
JAK2 induced by thrombin (Fig. 3B). Consistent with this both 
PDBu (1 PM) and A23 187 (2 ,LM) induced tyrosine phospho- 
rylation of JAK2 and, when given in combination, produced 
an effect greater than that produced by either stimulus alone 
(Fig. 3C). These data suggest hat phosphorylation of JAK2 by 
thrombin may occur downstream of second messenger forma- 
tion. 
t 
Fig. 3. (A) The effect of tyrosine kinase inhibitors on tyrosine phospho- 
rylation of JAK2 stimulated by thrombin (1 unit/ml): lane 1, basal; lane 
2, 10 PM staurosporine + 1 unit/ml thrombin; lane 3, 300 ,LLM 
ST271 + 1 unit/ml thrombin; lane 4,1 unit/ml thrombin. 4OOfll aliquots 
of platelets (8 x lO*/ml) were incubated with staurosporine (1 min) or 
ST271 (5 min) at 37°C before addition of stimuli. After 3 min, platelets 
were lysed and JAK2 was immunoprecipitated with antLJAK2 anti- 
body from Santa Cruz Biotechnology in non-denaturing conditions and 
immunoblotted with antiphosphotyrosine antibody as detailed above. 
(B) Effect of protein kinase C inhibition and intracellular calcium chela- 
tion on tyrosine phosphorylation of JAK2 stimulated by thrombin 
(I unit/ml): lane 1, basal; lane 2, IO PM Ro 3 l-8220 + 1 unit/ml throm- 
bin; lane 3,40 PM BAPTA-AM + 1 unit/ml thrombin; lane 4, 1 unit/ml 
thrombin. Platelets were treated with 10 PM Ro 31-8220 for I min or 
40,uM BAPTA-AM for 15 min, and then exposed to 1 unit/ml thrombin 
for 3 min. Immunoprecipitation (with anti-JAK2 serum from UBI) and 
immunoblotting were carried out as described in part A. (C) Effect of 
ionophore A23 187 and PDBu on tyrosine phosphorylation of JAK2. 
Washed platelets were incubated for 5 min with the following additions: 
lane 1, solvent; lane 2, 1 PM PDBu and 2 ,LLM A23187; lane 3, 2 PM 
A23 187; lane 4, 1 PM PDBu. JAK2 was immunoprecipitated from the 
lysed cells and immunoblotted with antiphosphotyrosine antibody as 
described in part A. In all cases, similar results were obtained in at least 
two other experiments. 
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4. Discussion References 
A number of studies have recently demonstrated the impor- 
tance of the JAK family of tyrosine kinases in signal transduc- 
tion triggered by cytokines and growth factors. In the present 
study we demonstrate the presence of JAK2 in human platelets 
and provide the first evidence that JAK2 is phosphorylated 
downstream of the second messengers DG/PKC and IP,/Ca*‘. 
The molecular events which underlie JAK2 phosphorylation in 
platelets are not known, although it has been shown that JAK2 
undergoes autophosphorylation in other cells [7-91. 
The relatively slow onset in phosphorylation of JAK2 in 
platelets challenged with thrombin suggests that this kinase is 
unlikely to participate in the early events associated with plate- 
let activation, such as secretion, shape change and the binding 
of fibrinogen to its receptor, the integrin oz,i& (also known as 
glycoprotein IIb-IIIa). However, JAK2 phosphorylation may 
play a role in late events, such as cytoskeletal rearrangement 
or clot retraction, since these are associated with later stages 
of tyrosine phosphorylation [2]. Further studies are ongoing to 
establish the role of this protein kinase in platelet activation. 
In conclusion, the present study has shown that JAK2 is 
phosphorylated on tyrosine residues on activation of the 
phosphoinositide pathway. The demonstration that G protein- 
coupled receptors are able to induce tyrosine phosphorylation 
of JAK2 in platelets has important implications for the regula- 
tion of gene expression in other cell types. 
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